

March 27, 2025

Senator Beidle, Chair Senator Hayes, Vice Chair Health and Government Operations Committee Senate Finance Committee 3 East Miller Senate Office Building Annapolis, Maryland 21401

Dear Chair Beidle, Vice Chair Hayes, and members of the Committee:

The Leukemia and Lymphoma Society is grateful for the opportunity to provide comments in support of HB 820.

LLS' mission is to cure blood cancer and improve the quality of life of all patients and their families. In light of this mission, LLS supports legislative efforts aimed at increasing transparency, accountability, and patient protections in the use of artificial intelligence (AI) and other automated decision-making systems in healthcare and health insurance decision-making.

Al has the potential to transform healthcare by improving patient care, streamlining administrative processes, and reducing costs. However, the integration of Al in healthcare raises concerns around data privacy, patient safety, and the risk of worsening health disparities if not implemented carefully. To deploy Al tools responsibly, it is crucial to ensure proper safeguards exist to protect patients from adverse outcomes.

Specifically, AI systems should be transparent, fair to all, and accountable. They should also address biases in algorithms and ensure that AI benefits everyone, not just a select few. This includes comprehensive data privacy and security measures. Continuous quality monitoring and establishing clear best practices will help pave the way forward, while independent audits will help ensure that AI systems continue to be safe and effective over time.

HB 820 represents a critical step in securing proper guardrails to ensure AI tools are used carefully, ethically, and transparently while prioritizing patient safety and meaningful access to care.

We thank you and urge a favorable report on HB 820.

Sincerely,

Lauren Edwards Regional Director, State Government Affairs The Leukemia & Lymphoma Society lauren.edwards@lls.org | (804) 922-3446